Clinical Utility of Temozolomide in the Treatment of Malignant Paraganglioma: A Preliminary Report

Abstract

We report on the efficacy and safety of short-term administration of temozolomide, an inhibitor of nucleoside incorporation, in a 60-year-old woman with widespread hepatic metastases from a malignant paraganglioma. Temozolomide was orally administered in daily doses of 250 mg on days 1 to 5 and repeated every 28 days for five cycles. Clinical improvement was immediate and associated with weight gain, and further reduction in blood pressure without ortho-static intolerance. In addition, abnormal hepatic function was normalized and catecholamine production was significantly reduced. Except for mild nausea, adverse effects were virtually absent. Bone marrow function, renal function, and serum electrolytes remained normal; hemoglobin remained above 9 g/dl through treatment. The platelet count decreased but not to clinically meaningful levels. These responses allowed for a surgical debulking procedure to be performed safely without complications. The results suggest that temozolomide may be useful in presurgical preparation of patients with pheochromocytoma especially in those with widespread metastatic disease and poor physical condition. However, the present findings need confirmation in a larger study and the role of temozolomide in the long-term treatment of malignant paraganglioma/pheochromocytoma remains to be established.

Key words

pheochromocytoma - chemotherapy - hepatic function - catecholamine production

References

• 1 Averbuch S, Steakley C, Young R, Gelmann EP, Goldstein DS, Stull R, Keiser HR. Malignant pheochromocytoma: effective treatment with a combination of cyclophosphamide, vincristine, and dacarbazine.  Ann Intern Med. 1988;  109 267-374
• 2 Huang H, Abraham J, Hung E, Averbuch S, Merino M, Steinberg SM, Pacak K, Fojo T. Treatment of malignant pheochromocytoma/paraganglioma with cyclophosphamide, vincristine, and dacarbazine: recommendation from a 22-year follow-up of 18 patients.  Cancer. 2008;  113 2020-2028
• 3 Fitoussi O, Debled M, Masson B, Coindre JM, Kantor G, Bui BN. Advanced paraganglioma: a role for chemotherapy?.  Med Paediatr Oncol. 1999;  33 129-131
• 4 Pipas JM, Krywicki RF. Treatment of progressive metastic glomus jugulare tumor (paraganglioma) with gemcitabine.  Neuro Oncol. 2000;  2 190-191
• 5 Kruijtzer CM, Beijnen JH, Swart M, Schellens JH. Successful treatment with paclitaxel of a patient with metastatic extra-adrenal pheochromocytoma (paraganglioma). A case report and review of the literature.  Cancer Chemother Pharmacol. 2000;  45 428-431
• 6 Chrisoulidou A, Kaltsas G, Ilias I, Grossman AB. The diagnosis and management of malignant pheochromocytoma and paraganglioma.  Endocr Relat Cancer. 2007;  14 569-585
• 7 Joshua AM, Shereen E, Asa SL, Evans A, Broom R, Freeman M, Knox JJ. Rationale and evidence for sunitinib in the treatment of malignant paraganglioma/pheochromocytoma.  J Clin Endocrinol Metab. 2009;  94 5-9
• 8 Stevens MFG, Hickman JA, Langdom SP, Chubb D, Vickers L, Stone R, Baig G, Goddard C, Gibson NW, Slack JA, Newton C, Lunt E, Fitames C, Lavelle F. Antitumor activity and pharmocokinetics in mice of 8-carbamoyl-3-methyl-imidazole[5-1-d]-1,2,3,5-tetrazin-4(3 H)-one (CCRG81245; M & B 39831), a novel drug with potential as an alternative to dacarbazine.  Cancer Res. 1987;  47 5846-5852
• 9 Middleton M, Grob J, Aaronson N, Fierlbeck G, Tilgen W, Seifer S, Gore M, Aamdal S, Cebon J, Coates A, Dreno B, Henz M, Schadendorf D, Kapp A, Weiss J, Fraass U, Statkevich P, Muller M. Thatcher N. Randomized phase III study of Temozolomide versus dacarbazine in the treatment of patients with advanced metastic melanoma.  J Clin Oncol. 2000;  18 158-166 , Erratum in J Clin Oncol 2000; 18: 2351. Comments in J Clin Oncol 2000; 18: 2185
• 10 Stupp R, Mason W, van den Bent M, Weller M, Fisher B, Taphoorn MJB, Belanger K, Brandes AA, Marosi C, Bogdahn U, Curschmann J, Janzer RC, Gorlia T, Allgeier A, Lacombe D, Cairncross JG, Eisenhauer E, Mirimanoff RO. The European Organization for Research and Treatment of Cancer Brain Tumor and Radiotherapy Group and the National Cancer Institute of Canada Clinical Trials Group. Radiotherpay plus concomitant and adjuvant Temozolomide for glioblastoma.  N Engl J Med. 2005;  352 987-996
• 11 Kulke MH, Stuart K, Enzinger PC, Ryan DP, Clark JW, Muzikansky A, Vincitore M, Michelini A, Fuchs CS. Phase II study of temozolomide and thalidomide in patients with metastatic neuroendocrine tumors.  J Clin Oncol. 2006;  24 401-406

Correspondence